Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
Contact

News & Events

Revealing the true targets for next generation immunotherapies.
Learn More

Drug Discovery World

Date: April 24, 2026 |
MHRA approves clinical trial for ovarian cancer therapy  By Bruno Quinney, April 24, 2026 The UK’s Medicines and Healthcare products Regulatory […]
Read More

European Biotechnology Magazine

Date: April 23, 2026 |
Epitopea wins UK approval for therapeutic vaccine trial By Uta Mommert, April 23, 2026 CryptiVax-1001 is set to enter first-in-human testing […]
Read More

Manufacturing Chemist

Date: April 23, 2026 |
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer  The company has received regulatory approval from the […]
Read More

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Date: April 23, 2026 |
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, UK and MONTREAL, CANADA, 23 April 2026 – Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that it has received […]
Read More

Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield

Date: April 13, 2026 |
CAMBRIDGE, UK and MONTREAL, CANADA, 13 April 2026 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies […]
Read More

Genetic Engineering News

Date: April 1, 2026 |
Engineering Biology to Fight Cancer Solid tumors are heterogeneous with an immunosuppressive tumor microenvironment, but that is not slowing the […]
Read More
1 2 3 4

Upcoming Events

Connect with Epitopea at these upcoming events

News Categories

Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital